Alexion Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alexion Pharmaceuticals Inc.
Sales in most categories in US portfolio grew, led by Zicam, Therabreath and Hero. But slumps continued for Waterpik water flossers, the Flawless feminine hair-removal, skin and nail care line and the vitafusion and L’il Critter gummies and other vitamin, mineral and supplement products.
The firms’ partnership goes back to pre-merger Celgene, and BMS still has Dragonfly candidates in its pipeline. Ji Xing gets hypertension candidate from Phase Bio.
Excluding the multinational majors AstraZeneca and GSK, the UK has yet to produce a truly successful scaled pharma company, despite having boasted several innovative start-ups. Whether that represents a negative, however, is a matter for debate.
Novel agents targeting similar indications suggest potential commercial struggles across the therapeutic landscape, with battlegrounds taking shape between RSV vaccines, new mechanisms in major depression, and bispecifics for large B-cell lymphoma.
- Large Molecule
- Other Names / Subsidiaries
- Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
- AstraZeneca PLC
- AstraZeneca Rare Disease
- Enobia Pharma Corp.
- LogicBio Therapeutics, Inc.
- Portola Pharmaceuticals, Inc. (PTLA)
- Synageva BioPharma Corp.
- Syntimmune, Inc.
- Taligen Therapeutics, Inc.
- Wilson Therapeutics AB
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.